Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins

@article{Travica2013ColonCC,
  title={Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins},
  author={Sandra Travica and Klaus Pors and Paul M. Loadman and Steven D. Shnyder and Inger Johansson and Mohammed N. Alandas and Helen M. Sheldrake and Souren Mkrtchian and Laurence H. Patterson and Magnus Ingelman-Sundberg},
  journal={Clinical Cancer Research},
  year={2013},
  volume={19},
  pages={2952 - 2961}
}
Purpose: Cytochrome P450 2W1 (CYP2W1) is a monooxygenase detected in 30% of colon cancers, whereas its expression in nontransformed adult tissues is absent, rendering it a tumor-specific drug target for development of novel colon cancer chemotherapy. Previously, we have identified duocarmycin synthetic derivatives as CYP2W1 substrates. In this study, we investigated whether two of these compounds, ICT2705 and ICT2706, could be activated by CYP2W1 into potent antitumor agents. Experimental… Expand
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer
TLDR
A potential targeted therapeutic approach to manage HNCs is suggested by exploiting intratumoural CYP expression for metabolic activation of duocarmycin-based prodrugs such as ICT2700. Expand
Cytochrome P450 Binding and Bioactivation of Tumor-targeted Duocarmycin Agents.
Duocarmycin natural products are promising anti-cancer cytotoxins but too potent for systemic use. Re-engineering of the duocarmycin scaffold has enabled the discovery of prodrugs designed forExpand
Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors
TLDR
Analysis of CYP2W1 expression in the colon adenocarcinoma cell line HCC2998 revealed that the gene expression can be induced by e.g. the antitumor agent imatinib, linoleic acid and its derivatives, which suggests an adjuvant therapy to treatment with duocarmycins that thus would involve induction of tumor CYP 2W1 levels followed by the CYP1 activated duocARMycin prodrugs. Expand
The CYP2W1 enzyme: regulation, properties and activation of prodrugs
TLDR
The CRC specific localization of CYP2W1 and its effective prodrug activation makes it a very promising target for future development of cancer therapeutics. Expand
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.
TLDR
This study reports on synthetic and biological explorations of racemic seco-CI-MI, where MI is a 5-methoxy indole motif, and dehydroxylated analogues, and shows up to a 10-fold bioactivation of de-OH CI-MI and a fluoro bioprecursor analogue in CYP1A1-transfected cells. Expand
Expression Profile of CYP1A1 and CYP1B1 Enzymes in Colon and Bladder Tumors
TLDR
The study reveals active CYP1 overexpression in human tumors and uncovers the potential use of CYp1 enzymes and mainly CYP 1B1 as targets for cancer therapy. Expand
Expression Profile of CYP 1 A 1 and CYP 1 B 1 Enzymes in Colon and Bladder Tumors
Background: The cytochrome P450 CYP1A1 and CYP1B1 enzymes are involved in carcinogenesis via activation of pro-carcinogenic compounds to carcinogenic metabolites. CYP1A1 and CYP1B1 have shownExpand
Cytochrome P450 2W1 (CYP2W1) – ready for use as the biomarker and drug target for cancer?
  • Yan Pan, E. Ong
  • Biology, Medicine
  • Xenobiotica; the fate of foreign compounds in biological systems
  • 2017
TLDR
Catalytic activity of CYP2W1 should be tested on a wider spectrum of endogenous and exogenous substances before its use as the drug target of cancer because of its characteristic cancer-specific expression. Expand
Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas
TLDR
It is concluded that normal adrenal tissue lacks P450 2W1 enzyme expression; also, adrenocortical carcinomas generally do not express the enzyme, underline the colon cancer specificity of CYP2W1 enzymes expression. Expand
The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases
TLDR
High CYP2W1 expression is seen in 26% of primary CRC and in 48% of corresponding liver metastases, which opens possibilities for new targeted therapies to metastatic CRC in the future. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1.
TLDR
CYP2W1 represents a tumor-specific P450 isoform with potential importance as a drug target in cancer therapy and was seen following demethylation by 5-Aza-2'-deoxycytidine. Expand
Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
TLDR
It is established that drug-activating CYP genes may be useful for the development of novel combined chemotherapy/gene therapy strategies for cancer treatment utilizing established cancer chemotherapeutic agents. Expand
Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy
TLDR
The selective expression in some forms of cancers and the low expression in normal tissues render CYP2W1 as a possible drug target during cancer therapy. Expand
Colorectal Cancer-Specific Cytochrome P450 2W1: Intracellular Localization, Glycosylation, and Catalytic Activity
TLDR
The study identifies for the first time a cytochrome P450 enzyme with a luminal ER orientation and still retaining catalytic activity and suggests the possibility of using CYP2W1 as a drug target in the treatment of colon cancer using antibodies and/or specific CYP 2W1 activated prodrugs. Expand
Expression of CYP2W1 in colon tumors: regulation by gene methylation.
TLDR
The expression of CYP2W1 is colon tumor-specific and is associated with methylation status of the CYP1W1 gene, suggesting a potential causal link between the gene hypomethylation and its enhanced expression. Expand
CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
TLDR
The results indicate that CYP-P450 isoforms play an important role in mediating benzothiazole activity, and CYP2W1 is important for bioactivation of GW-610 in CRC cells. Expand
Cytochrome P450 1B1: a novel anticancer therapeutic target.
TLDR
This review highlights the tremendous potential of this enzyme as a novel cancer therapeutic target and the therapeutic strategy, which is at the most advanced stage of development, is a CYP1B1-based vaccine which has already successfully completed a clinical trial. Expand
Cytochrome P450s in the development of target-based anticancer drugs.
TLDR
This review summarizes the merits and limitations of these expression systems for an optimized production of individual CYP isoforms, and their usefulness in the discovery and development of target-based, safe and efficacious NCEs for the treatment of cancer. Expand
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells
TLDR
Results show that an enzyme playing a role in the L-serine biosynthesis could be implicated in colon cancer progression and chemoresistance and indicate that PSAT1 represents a new interesting target for CRC therapy. Expand
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
  • P. Roy, D. Waxman
  • Biology, Medicine
  • Toxicology in vitro : an international journal published in association with BIBRA
  • 2006
TLDR
P450 GDEPT has several important features that make it a clinically attractive strategy for cancer treatment, including the substantial bystander cytotoxicity of P450 prodrugs such as cyclophosphamide and ifosfamide, the ability to use human P450 genes and thereby avoid an immune response to the therapeutic gene, and the potential to decrease systemic exposure to active drug metabolites by selective inhibition of hepatic P450 activity. Expand
...
1
2
3
4
...